{"id":6573,"date":"2017-04-24T12:40:12","date_gmt":"2017-04-24T16:40:12","guid":{"rendered":"https:\/\/medicarereport.org\/?p=6573"},"modified":"2017-04-24T12:40:12","modified_gmt":"2017-04-24T16:40:12","slug":"as-a-competitor-encroached-mylan-took-one-state-to-court-to-push-epipen-sales-documents-show","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=6573","title":{"rendered":"As a competitor encroached, Mylan took one state to court to push EpiPen sales, documents show"},"content":{"rendered":"<p>(By Ike Swetlitz for STAT)<\/p>\n<p>The pharmaceutical company Mylan has developed a reputation for fighting tooth-and-nail to promote its flagship product, the EpiPen. <a href=\"https:\/\/www.statnews.com\/2017\/04\/24\/mylan-west-virginia-lawsuit\/?_hsenc=p2ANqtz-88FMvkZ09_BQkRjcLT8MeavQeIskHthf8DX4ge06-GkXUXllfbtvr1hdDQpLgHJ0zrdbo0p7EqS3ofbW-91oDucewxqQ&amp;_hsmi=51092452\" target=\"_blank\">Continue reading article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"stat-logo\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Ike Swetlitz for STAT) The pharmaceutical company Mylan has developed a reputation for fighting tooth-and-nail to promote its flagship<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-6573","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/6573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6573"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/6573\/revisions"}],"predecessor-version":[{"id":6574,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/6573\/revisions\/6574"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}